This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • An Open-Label Study of Aripiprazole Lauroxil in Su...
Clinical trial

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Read time: 1 mins
Last updated:1st Dec 2014

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Estimated Enrollment: 140
Study Start Date: December 2014
Estimated Study Completion Date: July 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Aripiprazole Lauroxil - A
- Experimental: Aripiprazole Lauroxil - B
- Experimental: Aripiprazole Lauroxil - C
- Experimental: Aripiprazole Lauroxil - D

Category Value
Study start date 2014-12-01

View full details